Utama › Kanser Darah › Oklahoma
Kajian klinikal Kanser Darah di Oklahoma
8 kajian untuk Kanser Darah sedang mencari peserta di lokasi di Oklahoma.
Bandar di Oklahoma
Teks kajian rasmi (Bahasa Inggeris)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0082), Tulsa
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Mercy Hospital Oklahoma City, Oklahoma City
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 17 Sep 2026 · NCT04242095Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- OU Health Stephenson Cancer Center, Oklahoma City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT06001788PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- OU Health Physicians - Infectious Disease Clinic, Oklahoma City
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT06665100A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Oklahoma Health Science Center, Oklahoma City
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
- University of Oklahoma Health Sciences Center, Oklahoma City
Mengambil pesertaFasa 3
Umur 2 hingga 18 · Semua jantina · Dikemas kini 5 Mei 2026 · NCT05711667A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- OU Health Stephenson Cancer Center, Oklahoma City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Mac 2026 · NCT05735184Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.